Alnylam Pharmaceuticals (ALNY) PT Raised to $116.00 at Stifel Nicolaus

Share on StockTwits

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective raised by Stifel Nicolaus from $110.00 to $116.00 in a research note issued to investors on Monday, BenzingaRatingsTable reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC restated a buy rating and set a $135.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, February 8th. Cantor Fitzgerald restated a buy rating and set a $135.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, February 7th. ValuEngine downgraded shares of Alnylam Pharmaceuticals from a strong-buy rating to a buy rating in a report on Wednesday, January 2nd. Guggenheim started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, December 17th. They issued a buy rating and a $105.00 price target on the stock. Finally, Cowen reiterated a buy rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 6th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $128.39.

Shares of Alnylam Pharmaceuticals stock opened at $88.53 on Monday. Alnylam Pharmaceuticals has a one year low of $60.27 and a one year high of $124.21. The company has a quick ratio of 6.56, a current ratio of 6.69 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $9.55 billion, a price-to-earnings ratio of -11.69 and a beta of 2.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 7th. The biopharmaceutical company reported ($2.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.27) by $0.18. Alnylam Pharmaceuticals had a negative net margin of 1,016.58% and a negative return on equity of 50.82%. The firm had revenue of $21.00 million for the quarter, compared to the consensus estimate of $18.03 million. During the same quarter in the prior year, the company posted ($1.20) earnings per share. The company’s revenue for the quarter was down 44.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -8.68 EPS for the current year.

Large investors have recently made changes to their positions in the company. ETF Managers Group LLC lifted its holdings in Alnylam Pharmaceuticals by 15.7% in the 4th quarter. ETF Managers Group LLC now owns 1,086 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 147 shares in the last quarter. Advisors Asset Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.9% in the 4th quarter. Advisors Asset Management Inc. now owns 17,883 shares of the biopharmaceutical company’s stock worth $1,304,000 after acquiring an additional 155 shares during the last quarter. M&T Bank Corp increased its stake in shares of Alnylam Pharmaceuticals by 3.7% in the 4th quarter. M&T Bank Corp now owns 5,305 shares of the biopharmaceutical company’s stock worth $387,000 after acquiring an additional 188 shares during the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co increased its stake in shares of Alnylam Pharmaceuticals by 40.0% in the 4th quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 700 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 200 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 10.2% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,778 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 350 shares during the last quarter. Hedge funds and other institutional investors own 86.88% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Further Reading: What is the 52-week high/low?

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.